[Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?]

Date publication

mai 2019

Journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ESCHWEGE Pascal , Pr HUBERT Jacques

Tous les auteurs :
Baydaroglu E, Eschwège P, Hubert J, El Osta R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31151915

Résumé

Phosphodiesterase type 5 inhibitors (PDE5i) are the first-line treatment of erectile dyfunction (ED). Cost of PDE5i is not covered by health insurance company in France. Few studies have examined the potential impact of the introduction of generic products of PDE5i on price non-compliance. The aim of the study was to compare the non-compliance rate because of price among patients treated for DE with generics of PDE5i and those treated with brand-name medications.

Mots clés

Adherence, Causes de dysfonction érectile, Cost, Coût, Dysfonction érectile, ED causes, Erectile dysfunction, IPDE5, Observance, PDE5 inhibitors

Référence

Prog. Urol.. 2019 May 28;: